News coverage about Juno Therapeutics (NASDAQ:JUNO) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Juno Therapeutics earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.3525644484408 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Contrasting Stemline Therapeutics (STML) & Juno Therapeutics (JUNO) (americanbankingnews.com)
- Juno Therapeutics, Inc. (JUNO) to hit EPS growth of -6.30% for this year – Wallstreet Investorplace (wallstreetinvestorplace.com)
- Saudi PIF Could Even Be Big Without Aramco (swfinstitute.org)
- Attempt to Shakeup Active Momentum on New Compulsions- Juno Therapeutics, Inc. (NASDAQ:JUNO) – Stock News Stop (stockmarketstop.com)
- Form 4 Juno Therapeutics, Inc. For: Mar 05 Filed by: EVNIN ANTHONY B – StreetInsider.com (streetinsider.com)
Shares of Juno Therapeutics (NASDAQ:JUNO) remained flat at $$86.96 during trading hours on Wednesday. The stock had a trading volume of 2 shares, compared to its average volume of 6,000,000. The stock has a market capitalization of $9,930.00, a P/E ratio of -16.16 and a beta of 3.24. Juno Therapeutics has a 1 year low of $19.62 and a 1 year high of $87.01. The company has a current ratio of 3.61, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.
In other news, CEO Hans Edgar Bishop sold 270,250 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $46.17, for a total transaction of $12,477,442.50. Following the completion of the transaction, the chief executive officer now directly owns 2,772,679 shares in the company, valued at approximately $128,014,589.43. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Robert Azelby sold 1,816 shares of the business’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $44.96, for a total value of $81,647.36. Following the transaction, the executive vice president now owns 70,832 shares of the company’s stock, valued at $3,184,606.72. The disclosure for this sale can be found here. Insiders have sold a total of 473,031 shares of company stock valued at $27,031,205 over the last three months. Company insiders own 15.08% of the company’s stock.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.